TLC analysis was done using pre-coated silica gel plates. FT-IR spectra were carried out on Bruker RFS100/S spectrophotometer (BioRad, Cambridge, MA, USA) using KBr pellets in the 400-4000 cm -1 range. 1 H NMR, 13 C NMR, 1 H-1 H COSY and 13 C-1 H COSY spectra were recorded on a Bruker AV 300 spectrometer using TMS as an internal standard. The high-resolution mass spectra (HRMS) were recorded on an IonSpec FT-CR mass spectrometer with ESI resource. UV spectra were recorded at room temperature on a TU-2450 spectrophotometer (Puxi Analytic Instrument Ltd. of Beijing, China) equipped with 1.0 cm quartz cells.
The prepared compounds were evaluated for their antibacterial activities against Gram-positive bacteria (Staphylococcus aureus ATCC25923, Methicillin-resistant Staphylococcus aureus N315 (MRSA), Bacillus subtilis ATCC6633) and Micrococcus luteus ATCC4698), Gram-negative bacteria (Escherichia coli JM109, Escherichia coli DH52, Shigella dysenteriae, Pseudomonas aeruginosa ATCC27853, Bacillus proteus ATCC13315 and Bacillus typhi). The bacterial suspension was adjusted with sterile saline to a concentration of 1 × 10 5 CFU. Initially the compounds were dissolved in DMSO to prepare the stock solutions, then the tested compounds and reference drugs were prepared in Mueller-Hinton broth (Guangdong huaikai microbial sci. & tech co., Ltd, Guangzhou, Guangdong, China) to obtain the required concentrations of 512, 256, 128, 64, 32, 16, 8, 4 , 2, 1, 0.5 μg/mL. These dilutions were inoculated and incubated at 37 ºC for 24 h.
Antifungal Assays
The newly synthesized compounds were evaluated for their antifungal activities against Candida albicans ATCC10231, Candida mycoderma ATCC9888, Candida utilis ATCC9950, Aspergillus flavus ATCC204304 and Beer yeast. A spore suspension in sterile distilled water was prepared from one day old culture of the fungi growing on Sabouraud agar (SA) media. The final spore concentration was 1−5 × 10 3 spore mL -1 . From the stock solutions of the tested compounds and reference antifungal drug Fluconazole, dilutions in sterile RPMI 1640 medium (Neuronbc Laboraton Technology CO, Ltd, Beijing, China) were made resulting in eleven wanted concentrations (0.5 to 512 μg/mL) of each tested compound. These dilutions were inoculated and incubated at 35 ºC for 24 hours. 
3 Development of Aqueous Solubility in Phosphate Buffer (pH 7.4)
A standard solution was prepared by precisely weighing amount (generally 1 mg) of sample and dissolving in 10 mL CH 3 OH. The standard solution was scanned by UV to determine the wavelength of maximum absorbance, diluting as necessary. A saturated solution was prepared by stirring magnetically a small volume of pH 7.4 phosphate buffer solution in the presence of excess sample for 3 h, then the excess solid compound was filtered. Afterwards, the saturated solution was scanned by UV at the wavelength of the absorption maximum. Total solubility was dedermined by the relationship C' = A'C/A. Where C = concentration of standard solution in mg/mL, A = absorbance of the standard solution (correcting for any dilutions), A' = absorbance of the saturated solution (correcting for any dilutions), and C' = concentration of saturated solution in mg/mL. 
4 Time−Kill Kinetics Assay
The bactericidal activity evaluated by performing time kill kinetics assay. This gives the imformation about the rate at which the compounds are acting on bacteria. Briefly, MRSA bacterium was grown in suitable growth medium at 37 o C for 6 h and diluted. Compound 7a was added to the bacterial solution (MRSA of approximately 1.8  10 5 CFU/mL) at concentrations of 4  MIC in a 96-well plate and the mixture was incubated at 37 o C. At different time intervals (0, 1, 2, 3, 4, 5, 6, 7h) , aliquots (20 μL) from the solution were taken out and serially diluted 10-fold in 0.9% sodium chloride. Then 20 μL of the dilutions was plated on yeast−dextrose agar plates and incubated at 37 °C for 24 h. The bacterial colonies were counted, and results are represented in logarithmic scale: log 10 (CFU/mL) vs time (in hours).
5 Development of Resistance to Compound 7a
Considering the high-level resistance of Norfloxacin to MRSA strains, we selected the representative compound 7a to investigate the developing rate of bacterial resistance according to the paper "J. Hoque; M. M. Konai; S. Gonuguntla; G. B. Manjunath; S. Samaddar; V. Yarlagadda and J. Halar. J. Med. Chem., 2015, 58, 5486". We exposed a standard strain of MRSA towards increasing concentrations of compound 7a from original MIC for sustained passages and determined the MIC values of compound 7a for each passage of MRSA. 
Interactions with

DNA Cleavage Eexperiments
The plasmid pUC19 DNA was treated with different compounds in the buffer(5 mM Tris-HCl/50 mM NaCl, pH = 7.0) to a total volume of 20 μL. After incubation at 37 °C for a certain time, the solution was quenched by the addition of 6×loading buffer (2 μL). Then, the resulting solutions were loaded on a 0.8% agarose gel containing gold view dye. Gel electrophoresis was carried out at 100 V for 0.5 h in 1 × TAE buffer, and then the plasmid bands were visualized by a transilluminator and photographed. 
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